1 ptible to piperacillin and 100% resistant to ticarcillin.

2 inolones, but it is resistant to ampicillin, ticarcillin, and cefazolin.

3 acae versus ampicillin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavulanate and with P. aer

4 e and with P. aeruginosa versus mezlocillin, ticarcillin, and ticarcillin-clavulanate.

5          The most notable exceptions include ticarcillin-clavulanate and ampicillin, both of which en

6 illin-sulbactam, aztreonam, ticarcillin, and ticarcillin-clavulanate and with P. aeruginosa versus me

7  demonstrates that meropenem, cefotaxime and ticarcillin-clavulanate are associated with significantl

8 g of piperacillin-tazobactam, meropenem, and ticarcillin-clavulanate conducted in 5 intensive care un

9 actam, 256 microg/ml versus 4 microg/ml; and ticarcillin-clavulanate, 512 microg/ml versus 16 microg/

10 antianaerobic activity, including cefotetan, ticarcillin-clavulanate, and imipenem-cilastin.

11 bilities but only with ampicillin-sulbactam, ticarcillin-clavulanate, and/or clindamycin.

12 peracillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefotetan, ceftriax

13 ipants commenced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to

14 uginosa versus mezlocillin, ticarcillin, and ticarcillin-clavulanate.

15 was seldom observed in children treated with ticarcillin-clavulanic acid (T/C), we conducted a study

16 mycin, clindamycin, piperacillin-tazobactam, ticarcillin-clavulanic acid, metronidazole, cefotetan, a

17 spite intensive antimicrobial treatment with ticarcillin, gentamicin and vancomycin or levofloxacin e

18 aei displayed resistance to piperacillin and ticarcillin in 53 and 71% of the isolates, respectively.

19 actam antibiotic temocillin (6-alpha-methoxy-ticarcillin) shows stability to most extended spectrum b